Nathan Reed
Psychiatric/Mental Health · Greenville, SCNPI 1467148536
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations.
Across 263 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$677
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$646
- Otsuka America Pharmaceutical, Inc.$551
- Axsome Therapeutics, Inc.$312
- Lundbeck LLC$290
- Takeda Pharmaceuticals U.S.A., Inc.$277
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,45599%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $677 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $646 |
| Otsuka America Pharmaceutical, Inc. | 34 | $551 |
| Axsome Therapeutics, Inc. | 15 | $312 |
| Lundbeck LLC | 16 | $290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $277 |
| Idorsia Pharmaceuticals US Inc | 8 | $168 |
| Johnson & Johnson | 8 | $159 |
| Argenx US, Inc. | 4 | $145 |
| Neurocrine Biosciences, Inc. | 6 | $121 |
| Eisai Inc. | 5 | $120 |
| Alkermes, Inc. | 5 | $115 |
| Almatica Pharma LLC | 5 | $112 |
| Biogen | 6 | $109 |
| Vanda Pharmaceuticals Inc. | 5 | $97 |
| Bausch Health US, LLC | 5 | $94 |
| Tris Pharma Inc | 5 | $93 |
| Noven Therapeutics, LLC | 5 | $91 |
| Teva Pharmaceuticals USA, Inc. | 3 | $81 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| TG Therapeutics, Inc. | 2 | $54 |
| Lilly USA, LLC | 1 | $23 |
| EMD Serono, Inc. | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Livanova USA, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Cycle Pharmaceuticals Inc | 1 | $15 |
How this compares
$4,514 in reported general payments places this provider in the 85th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 46 | $79,323 |
| RexultiBrexpiprazole | 21 | $34,621 |
| CaplytaLumateperone Tosylate | 14 | $24,555 |
| TrintellixVortioxetine Hydrobromide | 33 | $23,211 |
| Lurasidone Hcl | 13 | $6,336 |
| Aripiprazole | 107 | $4,900 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 49 | $3,392 |
| Bupropion XlBupropion Hcl | 136 | $2,591 |
| Clonazepam | 218 | $2,361 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 183 | $1,895 |
| Atomoxetine Hcl | 17 | $1,568 |
| Eszopiclone | 28 | $1,551 |
| Buspirone Hcl | 132 | $1,406 |
| Quetiapine Fumarate | 185 | $1,325 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 40 | $1,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $677 | $79,32346 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $551 | $34,62121 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $646 | $24,55514 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $277 | $23,21133 claims |
| Lilly USA, LLCOlanzapine | $23 | $23123 claims |
| Almatica Pharma LLCSertraline Hcl | $112 | $20349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Greenville
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
- Lauren DyerGreenville$16K
- Melissa BrownGreenville$16K
- William HendricksGreenville$13K
- Carrie BallengerGreenville$11K
- Gregory SmithGreenville$9K
- Svetlana RobinsonGreenville$8K
- Jared CarboneGreenville$7K
- Anglique RichGreenville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.